Research
Hormonal
GLP-1 receptor agonists are associated with a higher frequency of gastrointestinal adverse events (nausea, vomiting, diarrhea) compared to placebo, although the risk of serious adverse events like pancreatitis remains comparable.
Expect gastrointestinal side effects like nausea and diarrhea when starting GLP-1 medications. These are common but usually mild to moderate. Serious side effects like pancreatitis are rare and occur at similar rates to placebo. Discuss management strategies with your provider to maintain treatment.
StrongQualifiesHIGH confidence
Across trials, GLP-1 RAs were consistently associated with a higher frequency of gastrointestinal adverse events compared to placebo, including nausea (14%–28% vs. 5%–10%), vomiting (6%–12% vs. 2%–4%), and diarrhea (8%–20% vs. 4%–7%). The risk of pancreatitis and serious adverse events remained comparable to placebo.
Why this rating
Based on aggregate data from 22 RCTs.
Source
Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review
Jena Velji-Ibrahim et al. · Journal of Obesity · 2025
systematic_review · n=41757Cited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →